Sanner, Mark A., “Selective dopamine D4 receptor antagonists”, Exp. Opin. Ther. Patents, 1998, 8(4), pp. 383-393. |
Robertson, D. W. “Recent progress in serotonin (5-HT)1A receptor modulators”, Ann. Rep. Med. Chem., 1995, 30, pp. 1-9. |
Wolff, M. C. et al.., “Pharmacological profile of LY301317, a potent and selective 5-HT1a agonist”, Drug Dev. Res., 1997, 40, pp. 17-34. |
MKC-242, Drugs of the Future, 1997, 22, pp. 225-228. |
Sharma, R. P., Shapiro, L. E. “The 5HT1a receptor system: possible implication for schizophrenic negative symptomatology”, Psych. Ann., 1996, 26, pp.88-92. |
Wadenberg, M. L. “Serotonergic mechanisms in neuroleptic-induced catalepsy in the rat”, Neurosci. Biobehav. Rev., 1996, 20, pp. 325-339. |
Artigas, F. et al., “Acceleration of the effect of selected antidepressant drugs in major depression by 5-HT1a antagonists”, Trends Neurosci., 1996, 19, pp. 378-383. |
Shiue, C. Y. et al., “p-[18F]-MPPF: a potential radioligand for PET studies of 5-HT1a receptors in humans”, Synapse, 1997, 25, pp. 147-154. |
Ramage, A. G. and Fozard, John R., “Exidence that the putative 5-HT1A receptor agonists, 8-OH-DPAT and ipsapirone, have a central hypotensive action that differs from that of clonidine in anesthetised cats”, Eur. J. Pharmacol., 1987, 138, pp. 179-191. |
DeVry, J., “5HT1A receptor agonists: recent developments and controversial issues”, Psychopharmacol., 1995, 12, 121, p. 1-26. |
McCall, R. B., Clement, M. E. “Role of serotonin 1A and serotonin 2 receptors in the central regulation of the cardiovascular system”, Pharmacol. Rev., 1994, 46, pp. 231-243. |
Neal-Beliveau, B. S., “Serotonergic involvement in haloperidol induced catalepsy”, J. Pharmacol. Exp. Ther., 1993, 265, pp. 207-217. |